Medication info
JanuaTin Duo Extended Release Tablet 100/1000 mg

JanuaTin Duo Extended Release Tablet 100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.37mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Pamgen Science Co., Ltd.
Appearance
Bright blue, double convex, oval-shaped extended-release film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300609 · Approved 2023.02.17 · Insurance code 670105420

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients receiving metformin: For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the patient’s current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start this drug at a dose of 2 tablets of 50/1000 mg extended-release tablet once daily. 3. When adequate glycemic control cannot be achieved with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other conditions that may increase the risk of lactic acidosis may use this drug with the following dose adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Pamgen Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. It is especially effective when used in conjunction with dietary and exercise regimens, as sitagliptin and metformin work together to help maintain stable blood sugar levels. If blood sugar management is difficult, improvements can be made through this medication, so it is essential to take it consistently while also managing lifestyle habits.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug. 2. Patients receiving metformin: For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 100 mg and the patient’s current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start this drug at a dose of 2 tablets of 50/1000 mg extended-release tablet once daily. 3. When adequate glycemic control cannot be achieved with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other conditions that may increase the risk of lactic acidosis may use this drug with the following dose adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication is composed of two ingredients, sitagliptin and metformin, and is primarily used for blood sugar control in patients with type 2 diabetes. Severe allergic reactions may occur while taking this medication, so if skin rashes, hives, or difficulty breathing occur, discontinue use immediately and consult healthcare professionals. There is a risk of developing pancreatitis, which is inflammation of the pancreas; therefore, if symptoms such as abdominal pain, vomiting, or loss of appetite arise, it is crucial to visit a hospital promptly. This medication should not be used in patients with severely impaired kidney function or in states of severe infection, dehydration, or heart failure, and it should also be discontinued before and after tests using iodine contrast agents. It is safe for women who are pregnant or may become pregnant, as well as for breastfeeding mothers, to avoid taking this medication. During use, irregular meals, excessive exercise, and co-administration with specific medications may lead to serious side effects such as hypoglycemia or lactic acidosis, so caution is necessary. In particular, the metformin component can cause rare but fatal metabolic complications known as lactic acidosis, so it is essential to have regular kidney and liver function tests and to inform healthcare providers immediately of any unusual symptoms. Furthermore, this medication can reduce vitamin B12 levels in some patients, so if used for a long time, monitoring through blood tests is necessary. Alcohol consumption may increase the risk of side effects from this medication, so excessive drinking should be avoided during treatment. Temporary discontinuation of use may be needed during surgery or acute illnesses, resuming only after the patient's condition stabilizes. It is essential to continue treatment safely through regular blood glucose tests and kidney function checks while using this medication.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 21 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • hypoglycemia
  • severe hypoglycemia
  • severe and disabling arthralgia
  • blistering dermatosis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • rash
  • urticaria
  • cutaneous vasculitis
  • acute renal failure
  • constipation

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it should be stored at room temperature between 1 to 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Bright blue, double convex, oval-shaped extended-release film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.